Middle East & Africa Cancer Drug Market Outlook, 2031

2026

Middle East & Africa Cancer Drug Market Outlook, 2031

The Middle East and Africa Cancer Drug Market is segmented into By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Other Treatment Types); By Indication (Breast Cancer, Lung Cancer (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), Colorectal Cancer, Prostate Cancer, Blood Cancers (Leukemia, Lymphoma, Multiple Myeloma), Cervical Cancer, Stomach / Gastric Cancer, Others (Liver Cancer, Kidney Cancer (Renal Cell Carcinoma), Ovarian Cancer, Bladder Cancer, Skin Cancer, Brain Tumor, Thyroid Cancer)); By Route of Administration (Oral, Injectable); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies / Drug Stores, Online Pharmacies).

Bonafide Research
13-03-2026
Pages : 76
Figures : 6
Tables : 21
Region : MEA
Category : Lifescience & Healthcare
Pharmaceutical

Schedule a Call

Buy Now Get Free sample

The Middle East and Africa Cancer Drug Market is expected to reach a market size of more than 22.85 Billion by 2031.

Historical Period2020-2024
Base Year2025
Forecast Period2026-2031
Largest MarketSaudi Arabia
Fastest Market United Arab Emirates
Market Difference(2026-31) USD 9.09
Format

Featured Companies

1. Johnson & Johnson Private Limited
2. Pfizer Inc.
3. Novartis International AG
4. AbbVie Inc.
5. AstraZeneca plc
6. Eli Lilly and Company
More...

Highend Report

Highend report of this product is available

View

New Report Guarantee

If you purchase this report now and we update it in next 100 days, get it free!

Cancer Drug Market Analysis

The Middle East and Africa cancer drug market represents one of the most dynamic and rapidly evolving oncology landscapes globally, characterized by stark internal contrasts between the well-resourced Gulf Cooperation Council nations and the severely constrained healthcare systems across sub-Saharan Africa, yet united by a shared trajectory of accelerating cancer burden, growing institutional commitment to oncology care improvement, and deepening pharmaceutical industry engagement that is progressively transforming the region into a commercially significant and strategically important market for global drug manufacturers. In terms of products, the market spans a broad therapeutic spectrum across two distinctly different sub-regions. Precision oncology medicines such as immunotherapies, monoclonal antibodies, and antibody-drug conjugates are available in the GCC and to a lesser extent in selected countries in Africa, while cytotoxic drugs, targeted therapies, hormonal therapies, and biosimilars collectively address the region's diverse cancer burden across breast, lung, colorectal, and hematologic malignancies. The GCC countries, particularly Saudi Arabia, the United Arab Emirates, Qatar, and Kuwait, have achieved access levels approaching those of developed markets for certain innovative therapies, while African nations remain predominantly reliant on conventional chemotherapy and generic medicines. Regulatory bodies in Middle East and Africa are expediting drug approvals and providing funding for oncology research, ensuring faster access to life-saving medications, while Saudi Arabia's Vision 2030 includes robust plans to expand oncology centers and equip hospitals with cutting-edge medical technologies, and governments across the region are allocating larger portions of their budgets to healthcare reflecting a growing commitment to tackling non-communicable diseases like cancer. According to the research report, " Middle East and Africa Cancer Drug Market Outlook, 2031," published by Bonafide Research, the Middle East and Africa Cancer Drug Market is expected to reach a market size of more than 22.85 Billion by 2031.The Middle East and Africa cancer drug market is experiencing a strategically significant wave of collaborations, licensing agreements, and partnership-driven growth initiatives that are collectively reshaping the competitive landscape and accelerating access to innovative oncological treatments across this highly heterogeneous region. The competitive landscape of the oncology cancer drugs market is characterized by intense rivalry among key players including pharmaceutical giants, with collaborations, mergers, and acquisitions being common strategies to expand product portfolios and market reach, and the market also witnessing the entry of biotechnology firms and startups adding to the competition. One of the most regionally significant partnership developments was the agreement between Kyowa Kirin International and NewBridge Pharmaceuticals, which permitted NewBridge to act as distributor for Kyowa Kirin International's rare disease portfolio across Algeria, Iraq, Libya, and Jordan, supporting the company's commitment to geographical expansion to meet the needs of patients across the international region. Alongside distribution partnerships, Rakuten Medical announced an exclusive licensing and commercialization agreement with Hikma Pharmaceuticals for the MENA region, bringing precision cell-targeting therapies based on its proprietary Alluminox platform to a market with significant unmet need in oncology. The region's own pharmaceutical manufacturing capacity remains concentrated in a small number of countries including South Africa, Egypt, Saudi Arabia, and the United Arab Emirates, with most sub-Saharan African markets relying almost entirely on imported finished oncology medicines. The market for cancer drugs in Middle East and Africa is poised for further growth through both local production and international partnerships, while the Middle East is witnessing an increase in collaborations between local research institutions and global pharmaceutical companies enhancing the region's clinical trial capabilities through knowledge exchange, resource sharing, and access to advanced technologies.

to Download this information in a PDF

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample

Market Dynamic

Market Drivers

• Rapidly Escalating Cancer Burden: The most foundational driver of the MEA cancer drug market is the accelerating rise in cancer incidence across the region, making it one of the most urgently expanding oncology markets globally. Among all WHO regions, MENA is projected to experience the highest increase in cancer cases over the coming decades, primarily because of population growth, aging, and lifestyle changes, with analyses revealing a near doubling of cancer incidence and prevalence across MENA countries between 1990 and 2019, accompanied by a significant increase in related mortality.
• Government Healthcare Investment: Market Challenges• Severe Affordability Constraints: The most pervasive challenge confronting the MEA cancer drug market is the stark and widening gap between the cost of innovative oncology therapies and the financial capacity of the region's highly heterogeneous healthcare systems and patient populations. The expensive nature of cancer therapies, especially immunotherapies and targeted drugs, limits affordability and accessibility for many patients, with the region also facing unique challenges including late-stage diagnosis, limited access to advanced diagnostic and therapeutic options, disparities in healthcare infrastructure, and financial constraints affecting treatment accessibility.
• Regulatory Fragmentation: A second critical challenge is the highly fragmented regulatory landscape across the MEA region, where each national health authority operates with distinct approval requirements, clinical evidence standards, and review timelines that collectively delay market access for innovative cancer drugs and create significant commercial complexity for pharmaceutical manufacturers. Following global launch, the registration process for an oncology product in the selected GCC and African countries may require an extended timeline with significant variations depending on regulatory frameworks and manufacturer strategy.

Market Trends

• Expansion of Generic Oncology Drugs: One of the most commercially impactful trends reshaping the MEA cancer drug market is the rapid expansion of biosimilar and generic oncology drugs, which is progressively improving treatment affordability and broadening patient access across both the GCC and African sub-regions. With the expiration of patents for major biologic drugs, biosimilars are gaining traction as cost-effective alternatives improving access to cancer treatments.
• Growing Adoption of Targeted Therapies: A transformative trend defining the future trajectory of the MEA cancer drug market is the progressive adoption of precision medicine principles, biomarker-driven treatment selection, and advanced targeted therapies and immunotherapeutic agents across leading healthcare institutions in the GCC and major African markets. The integration of biomarkers and genetic profiling is driving the shift toward personalized oncology treatments tailored to individual patient needs.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Research Analyst

Cancer Drug Segmentation

By Therapy Type	Chemotherapy
	Targeted Therapy
	Immunotherapy
	Hormonal Therapy
	Other Treatment Types
By Indication	Breast Cancer
	Lung Cancer
	Colorectal Cancer
	Prostate Cancer
	Blood Cancers
	cervical cancer
	Stomach/ Gastric Cancer
	Others
By Route of Administration	Oral
	Injectable
By Distribution Channel	Hospital Pharmacies
	Retail Pharmacies / Drug Stores
	Online Pharmacies

Targeted therapy is the largest segment in therapy type segmentation because it offers precise treatment by directly attacking cancer-specific molecular targets, improving efficacy while reducing systemic side effects, making it highly preferred in the Middle East and Africa region. Targeted therapy dominates the therapy type segment in the Middle East and Africa cancer drug market due to its ability to selectively inhibit cancer cell growth by focusing on specific genetic mutations, signaling pathways, and molecular markers while sparing healthy cells. Unlike conventional chemotherapy, which affects both malignant and normal cells and often causes severe side effects, targeted therapies provide better safety profiles, higher patient tolerance, and improved clinical outcomes, which makes them highly preferred by physicians and patients across the region. The adoption of targeted therapy is further supported by growing awareness of precision medicine and biomarker testing, allowing clinicians to identify patients who are most likely to benefit from specific treatments. Pharmaceutical companies are heavily investing in research and development, clinical trials, and collaborations with local hospitals and biotechnology firms to introduce novel targeted agents, including tyrosine kinase inhibitors, monoclonal antibodies, and small molecule inhibitors, addressing high unmet needs in cancers such as breast, lung, colorectal, and liver cancer. Regulatory frameworks in countries such as Saudi Arabia, South Africa, UAE, and Egypt provide faster approvals and clear guidelines for innovative oncology drugs, improving accessibility and patient adoption. Additionally, the expansion of hospital pharmacies, specialized oncology centers, and diagnostic facilities ensures effective administration, monitoring, and management of therapies. Rising healthcare expenditure, government initiatives for cancer management and patient education programs further enhance the adoption of targeted therapies. Furthermore, ongoing innovation in combination therapies that pair targeted agents with immunotherapies or chemotherapy is expanding treatment options and improving patient outcomes. The increasing availability of oral and home-based targeted therapies is also enhancing convenience and adherence, reinforcing its dominance in the region. Breast cancer is the largest segment in indication segmentation because of its high prevalence across the Middle East and Africa, widespread awareness programs, and the extensive availability of targeted, hormonal, and combination therapies. Breast cancer holds the largest share in the indication segment of the Middle East and Africa cancer drug market due to a combination of various epidemiological, clinical, and infrastructural factors. The region has seen rising incidence rates of breast cancer which is known to be driven by lifestyle changes, urbanization, and increasing life expectancy, creating strong demand for effective treatment options. Early detection and screening programs initiated by governments and non-profit organizations have improved diagnosis rates, allowing patients to access therapies at earlier stages when treatment outcomes are more favorable. Advanced treatment options such as targeted therapies, including HER2 inhibitors, hormonal therapies like selective estrogen receptor modulators, and combination regimens are widely adopted, offering better efficacy and reduced systemic toxicity compared to traditional chemotherapy. Pharmaceutical companies are investing in research and development, clinical trials, and partnerships with local hospitals and oncology centers to introduce innovative breast cancer treatments and expand their availability. Regulatory frameworks in countries such as Saudi Arabia, UAE, Egypt, and South Africa provide guidelines for fast-track approvals of breakthrough therapies, supporting timely patient access. Additionally, the expansion of hospital pharmacies, specialized oncology centers, and diagnostic laboratories facilitates safe administration, monitoring, and patient follow-up. Government initiatives and reimbursement programs are gradually improving affordability, while awareness campaigns encourage women to seek early treatment and adhere to prescribed therapies. The integration of precision medicine, companion diagnostics, and patient education programs further strengthens adoption rates. Moreover, increasing patient education and support programs are enhancing adherence to long-term treatment regimens, improving overall outcomes. Injectable administration is the largest segment in route of administration because most advanced cancer therapies, including chemotherapy, targeted drugs, and immunotherapies, require clinical supervision, controlled dosing, and precise delivery that can only be ensured in hospital or specialized settings. Injectable cancer drugs dominate the route of administration segment in the Middle East and Africa due to the clinical complexity, high potency, and safety requirements of most oncology therapies. Chemotherapy, immunotherapy, monoclonal antibodies, and certain targeted therapies are typically formulated for intravenous or subcutaneous delivery, allowing precise dosing and controlled infusion rates to maximize efficacy while minimizing adverse effects. Hospitals, oncology centers, and specialized infusion clinics provide the necessary infrastructure for safe preparation, storage, and administration of these therapies, which often require continuous monitoring for immune-related reactions or infusion-related complications. The preference for injectables is further supported by regulatory frameworks in countries such as Saudi Arabia, UAE, Egypt, and South Africa, which mandate hospital-based administration for high-risk oncology drugs to ensure patient safety and compliance with quality standards. Pharmaceutical companies are investing in advanced infusion technologies, safety devices, and clinical training programs to improve the efficiency and reliability of injectable therapy delivery. While oral therapies are growing, particularly for targeted agents and home-based regimens, injectables remain the preferred choice for first-line treatments and advanced-stage cancers due to their predictable pharmacokinetics and proven efficacy in clinical trials. The combination of robust hospital infrastructure, regulatory support, and the clinical requirements of high-potency cancer drugs ensures that injectable administration continues to dominate the Middle East and Africa cancer drug market. Continued investment in hospital networks, patient monitoring, and advanced delivery systems will further reinforce the dominance of injectable therapies. Additionally, the growing focus on combination therapies that integrate injectable agents with oral or targeted treatments is enhancing treatment outcomes Hospital pharmacies are the largest segment in distribution channel segmentation because they provide controlled access to high-cost and complex cancer drugs, ensure proper storage and administration, and offer integrated patient support, making them the preferred channel in the Middle East and Africa region. Hospital pharmacies dominate the distribution channel segment in the Middle East and Africa cancer drug market due to their ability to manage the storage, handling, and dispensing of advanced oncology therapies that require precise dosing and careful monitoring. Most cancer drugs, including injectable chemotherapies, immunotherapies, and targeted therapies, need controlled environments to maintain stability and efficacy, which hospital pharmacies are equipped to provide. These facilities also offer patient-centric services such as counseling, adherence monitoring, and management of side effects, which are crucial for complex treatment regimens. The presence of specialized oncology centers and hospital networks in countries such as Saudi Arabia, UAE, Egypt, and South Africa further strengthens the role of hospital pharmacies as the primary distribution channel. Regulatory frameworks often mandate that high-potency and high-cost drugs be dispensed through licensed hospitals to ensure safety, compliance, and proper reporting, further solidifying their dominance. Hospital pharmacies also support integrated care models by collaborating closely with oncologists, nurses, and diagnostic laboratories to coordinate treatment schedules, administer combination therapies, and provide follow-up care. While retail pharmacies and online pharmacies are expanding, particularly for oral therapies and home-based care, hospital pharmacies continue to lead due to their ability to manage complex therapies, ensure patient safety, and provide comprehensive support services. Also hospital pharmacies play a critical role in educating patients and caregivers about treatment protocols, side effect management and adherence strategies, enhancing overall outcomes. They also facilitate participation in clinical trials and access to newly approved therapies, ensuring patients benefit from the latest innovations.

to Download this information in a PDF

Cancer Drug Market Regional Insights

Saudi Arabia is the largest market in the Middle East and Africa region because of its advanced healthcare infrastructure, high healthcare expenditure, strong regulatory support, and widespread adoption of innovative cancer therapies. Saudi Arabia dominates the cancer drug market in the Middle East and Africa due to a combination of well-established healthcare systems, government initiatives, and increasing access to advanced oncology treatments. The country has invested heavily in building specialized oncology centers, hospital networks, and diagnostic laboratories, which ensure effective delivery and administration of complex therapies such as targeted treatments, immunotherapies, and combination regimens. Government support through national cancer control programs, early detection initiatives, and reimbursement policies has increased patient access to high-cost therapies and facilitated the introduction of innovative drugs. Regulatory frameworks in Saudi Arabia provide clear pathways for clinical trial approvals, fast-track drug registration, and compliance with international safety standards, which attract global pharmaceutical companies to launch their products in the market. Pharmaceutical firms are actively collaborating with hospitals, research institutions, and biotech companies to conduct clinical trials, develop novel therapies, and expand distribution networks, ensuring timely access to advanced treatment options. The rising prevalence of cancers such as breast, lung, colorectal, and blood cancers combined with growing awareness and screening programs, drives demand for effective treatments and reinforces market growth. Additionally, the increasing adoption of precision medicine, companion diagnostics, and patient support programs enhances treatment personalization and adherence, improving outcomes. With robust healthcare infrastructure, supportive policies, high patient awareness, and active investment from both government and private sectors, Saudi Arabia maintains its position as the largest and most influential market for cancer drugs. Moreover, the integration of digital health platforms and telemedicine services is improving patient monitoring and follow-up, enhancing the overall quality of oncology care. Investments in local manufacturing and supply chain optimization ensure consistent availability of advanced cancer drugs across the country.

to Download this information in a PDF

Don't pay for what you don't need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

Companies Mentioned

Johnson & Johnson Private Limited
Pfizer Inc.
Novartis International AG
AbbVie Inc.
AstraZeneca plc
Eli Lilly and Company
Roche Holding AG
BeOne Medicines

1. Executive Summary
2. Market Dynamics
2.1. Market Drivers & Opportunities
2.2. Market Restraints & Challenges
2.3. Market Trends
2.4. Supply chain Analysis
2.5. Policy & Regulatory Framework
2.6. Industry Experts Views
3. Research Methodology
3.1. Secondary Research
3.2. Primary Data Collection
3.3. Market Formation & Validation
3.4. Report Writing, Quality Check & Delivery
4. Market Structure
4.1. Market Considerate
4.2. Assumptions
4.3. Limitations
4.4. Abbreviations
4.5. Sources
4.6. Definitions
5. Economic /Demographic Snapshot
6. Middle East & Africa Cancer Drug Market Outlook
6.1. Market Size By Value
6.2. Market Share By Country
6.3. Market Size and Forecast, By Therapy Type
6.4. Market Size and Forecast, By Indication
6.5. Market Size and Forecast, By Route of Administration
6.6. Market Size and Forecast, By Distribution Channel
6.7. United Arab Emirates (UAE) Cancer Drug Market Outlook
6.7.1. Market Size by Value
6.7.2. Market Size and Forecast By Therapy Type
6.7.3. Market Size and Forecast By Indication
6.7.4. Market Size and Forecast By Route of Administration
6.7.5. Market Size and Forecast By Distribution Channel
6.8. Saudi Arabia Cancer Drug Market Outlook
6.8.1. Market Size by Value
6.8.2. Market Size and Forecast By Therapy Type
6.8.3. Market Size and Forecast By Indication
6.8.4. Market Size and Forecast By Route of Administration
6.8.5. Market Size and Forecast By Distribution Channel
6.9. South Africa Cancer Drug Market Outlook
6.9.1. Market Size by Value
6.9.2. Market Size and Forecast By Therapy Type
6.9.3. Market Size and Forecast By Indication
6.9.4. Market Size and Forecast By Route of Administration
6.9.5. Market Size and Forecast By Distribution Channel
7. Competitive Landscape
7.1. Competitive Dashboard
7.2. Business Strategies Adopted by Key Players
7.3. Porter's Five Forces
7.4. Company Profile
7.4.1. Roche Holding AG
7.4.1.1. Company Snapshot
7.4.1.2. Company Overview
7.4.1.3. Financial Highlights
7.4.1.4. Geographic Insights
7.4.1.5. Business Segment & Performance
7.4.1.6. Product Portfolio
7.4.1.7. Key Executives
7.4.1.8. Strategic Moves & Developments
7.4.2. AbbVie Inc.
7.4.3. Novartis AG
7.4.4. Pfizer Inc.
7.4.5. Eli Lilly and Company
7.4.6. AstraZeneca plc
7.4.7. BeOne Medicines
7.4.8. Johnson & Johnson
8. Strategic Recommendations
9. Annexure
9.1. FAQ`s
9.2. Notes
10. Disclaimer

Table 1: Influencing Factors for Cancer Drug Market, 2025
Table 2: Top 10 Counties Economic Snapshot 2024
Table 3: Economic Snapshot of Other Prominent Countries 2022
Table 4: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 5: Middle East & Africa Cancer Drug Market Size and Forecast, By Therapy Type (2020 to 2031F) (In USD Billion)
Table 6: Middle East & Africa Cancer Drug Market Size and Forecast, By Indication (2020 to 2031F) (In USD Billion)
Table 7: Middle East & Africa Cancer Drug Market Size and Forecast, By Route of Administration (2020 to 2031F) (In USD Billion)
Table 8: Middle East & Africa Cancer Drug Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 9: United Arab Emirates (UAE) Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 10: United Arab Emirates (UAE) Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 11: United Arab Emirates (UAE) Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 12: United Arab Emirates (UAE) Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 13: Saudi Arabia Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 14: Saudi Arabia Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 15: Saudi Arabia Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 16: Saudi Arabia Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 17: South Africa Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 18: South Africa Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 19: South Africa Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 20: South Africa Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 21: Competitive Dashboard of top 5 players, 2025

Figure 1: Middle East & Africa Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 2: Middle East & Africa Cancer Drug Market Share By Country (2025)
Figure 3: United Arab Emirates (UAE) Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 4: Saudi Arabia Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: South Africa Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 6: Porter's Five Forces of Global Cancer Drug Market

Cancer Drug Market Research FAQs

Targeted therapy leads due to its precision in attacking cancer cells with minimal systemic side effects.

Immunotherapy is expanding rapidly as it leverages the immune system for durable and effective cancer treatment.

Breast cancer is the largest due to high prevalence, early detection programs, and widespread availability of targeted and hormonal therapies.

Injectable therapies dominate because most advanced drugs require hospital-based administration and clinical monitoring

Related Reports

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted